doxorubicin,sotigalimab
apexigen
['doxorubicin', 'apex', 'sotigalimab', 'sarcoma', 'apexigen', '$apgn']
$apgn apexigen announces phase 2 data evaluating sotigalimab, its cd40 agonist antibody, in combination with doxorubicin in patients with advanced soft tissue sarcoma. data presented in a poster presentation on june 3, 2023 at the asco annual meeting. 
Financial news recaps and ticker rating curated by AI language models. Fine tuned on analyst articles and return alpha. More exposure to lesser known companies.